Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zotiraciclib - Adastra Pharmaceuticals/S*Bio

Drug Profile

Zotiraciclib - Adastra Pharmaceuticals/S*Bio

Alternative Names: SB-1317; TG 02 - S*Bio/Adastra-Pharmaceuticals; TG02; TG02 citrate; Zotiraciclib citrate

Latest Information Update: 04 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator S*BIO
  • Developer Adastra Pharmaceuticals; European Organisation for Research and Treatment of Cancer; Lee's Pharmaceutical; National Cancer Institute (USA); S*BIO
  • Class Antineoplastics; Heterocyclic compounds with 4 or more rings; Small molecules
  • Mechanism of Action CDC2 protein kinase inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 5 inhibitors; Extracellular signal-regulated MAP kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors; RNA polymerase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Anaplastic astrocytoma; Glioblastoma
  • No development reported Cancer; Chronic lymphocytic leukaemia; Diffuse intrinsic pontine glioma; Leukaemia; Multiple myeloma; Solid tumours

Most Recent Events

  • 02 Jun 2023 Efficacy and adverse events data from the phase Ib STEAM trial for Anaplastic astrocytoma and Glioblastoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 03 Nov 2022 National Cancer Institute plans a phase I/II trial in Glioma (Recurrent, Second-line therapy or greater) in USA (PO) (NCT05588141)
  • 28 Oct 2022 No recent reports of development identified for phase-I development in Diffuse intrinsic pontine glioma(In adolescents, In children, In infants, In neonates) in Unknown (PO, Capsule)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top